BiomX reports Q3 EPS 29c vs (31c) last year

“This past quarter was defined by significant advancements in our regulatory discussions with the Food and Drug Administration across our pipeline,” said Jonathan Solomon, Chief Executive Officer of BiomX (PHGE). “For BX004, we anticipate imminent FDA feedback regarding the clinical hold, and we have already received supportive guidance outlining potential Phase 3 development pathways that reflect recognition of the significant unmet need among cystic fibrosis patients treated with CFTR modulators. In parallel, we received additional positive FDA feedback confirming a clear clinical development path for BX011, our new fixed multi-phage cocktail targeting Staphylococcus aureus in diabetic foot infections, building on the success of our prior Phase 2 trial in diabetic foot osteomyelitis.”